scholarly journals Surgery for Cutaneous Squamous Cell Carcinoma and its Limits in Advanced Disease

2021 ◽  
Vol 11 (S2) ◽  
pp. e2021167S
Author(s):  
David Moreno-Ramírez ◽  
Francisca Silva-Clavería ◽  
Almudena Fernández-Orland ◽  
Noemí Eiris ◽  
Andrés Ruiz-de-Casas ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Therapeutic Option ◽  
Tumor Resection ◽  
Cutaneous Squamous Cell Carcinoma ◽  
R0 Resection ◽  
First Line ◽  
Neoadjuvant Immunotherapy ◽  
Therapeutic Landscape

Surgery remains the first-line therapeutic option for most patients with cutaneous squamous cell carcinoma (cSCC). However, in the current therapeutic landscape, surgery must attempt to the complete tumor resection (R0 resection) with the lowest risk of surgical complications. This double aim is usually accomplished through standard excision with clinical margins in patients with low-risk tumors or by some of the micrographically controlled surgery procedures for patients with tumors at high-risk of local recurrence and metastasis. Surgery is also a first-line treatment for nodal metastases of cSCC as well as an option to consider in patients who develop recurrences while receiving immunotherapy, or as a palliation procedure in patients with advanced tumors. Neoadjuvant immunotherapy, that is the use of a medical treatment before surgery, is under investigation in patients with cSCC. The decision-making process and guidelines recommendations regarding cSCC surgery are reviewed in this manuscript.  

scholarly journals 1064P Final results of CA209-9JC: A phase II study of first-line nivolumab in patients with advanced cutaneous squamous cell carcinoma

2021 ◽  
Vol 32 ◽  
pp. S885
Author(s):  
R. Ramella Munhoz ◽  
V.P. de Camargo ◽  
G. Nader Marta ◽  
M.M. Queiroz ◽  
J. Cury-Martins ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Squamous Cell ◽  
Phase Ii Study ◽  
Cutaneous Squamous Cell Carcinoma ◽  
First Line

scholarly journals Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab

2019 ◽  
Vol 12 (8) ◽  
pp. e229915
Author(s):  
Samantha Venkatesh ◽  
Ali Al-Haseni ◽  
Debjani Sahni
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Locally Advanced ◽  
Cutaneous Squamous Cell Carcinoma ◽  
First Line ◽  
Mutation Burden ◽  
The Right ◽  
Cell Death Protein ◽  
Potential Use

Currently, there are few effective therapies for locally advanced and metastatic cutaneous squamous cell carcinoma (cSCC); however, there is recent evidence supporting the use of immunological therapies in cSCC given the typically high mutation burden and association with immunosuppressed states. This report describes a 56-year-old man presenting with synchronous, invasive cSCC on the right temple and right dorsum of the hand deemed unfavourable for surgical resection. The patient was treated with nine infusions of programmed cell death protein 1 (PD-1) inhibitor therapy, pembrolizumab, with clinical and radiographical resolution of his lesions. This case illustrates the potential use of anti-PD-1 antibody as a first-line treatment in the setting of advanced, unresectable cSCC.

scholarly journals The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case Report

2021 ◽  
Vol 11 ◽  
Author(s):  
Xiaozhun Huang ◽  
Chunling Wang ◽  
Teng Ma ◽  
Zhangkan Huang ◽  
Houhong Zhou ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Therapeutic Option ◽  
Brca2 Mutation ◽  
Stage Iv ◽  
Clinical Activity ◽  
R0 Resection ◽  
Metastatic Setting ◽  
Radical Antegrade Modular Pancreatosplenectomy

Pancreatic squamous cell carcinoma (SCC) is a rare primary pancreatic malignancy with a poor prognosis. The median overall survival (OS) for metastatic setting is only 4 months and the optimal management remains poorly defined. In the present study, we report a 52-year-old female patient with stage IV primary SCC of the pancreas harboring a deleteous BRCA2 somatic mutation. After 10 cycles of chemotherapy of cisplatin combined with nanoparticle albumin-bound paclitaxel, metastatic lesions in the liver and lymph nodes achieved radiographic complete responses and pancreatic lesion shrank from 5.7 to 1.5 cm in diameter. The patient subsequently underwent a posterior radical antegrade modular pancreatosplenectomy with R0 resection and residual liver lesions were also resected. After 3 months, a tumor relapsed in the liver. She was then treated with olaparib combined with pembrolizumab and achieved stable disease on the liver lesion. The patient eventually died from cerebral hemorrhage with a long OS of 21 months. Our case demonstrated a favorable clinical activity and survival advantage of the combined cisplatin and nanoparticle albumin-bound paclitaxel, which might serve as a therapeutic option for the patient with BRCA-mutant pancreatic SCC.

scholarly journals Cutaneous Squamous Cell Carcinoma: From Biology to Therapy

2020 ◽  
Vol 21 (8) ◽  
pp. 2956 ◽  
Author(s):  
Roberto Corchado-Cobos ◽  
Natalia García-Sancha ◽  
Rogelio González-Sarmiento ◽  
Jesús Pérez-Losada ◽  
Javier Cañueto
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Molecular Basis ◽  
Checkpoint Inhibitors ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Drug Induced ◽  
Mutational Burden ◽  
Therapeutic Landscape ◽  
Increased Risk

Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors. Another purpose of this review is to explore the landscape of drugs that may induce or contribute to the development of CSCC. Beginning with the pathogenetic basis of these drug-induced CSCCs, we move on to consider potential therapeutic opportunities for overcoming this adverse effect.

Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin

2011 ◽  
Vol 29 (25) ◽  
pp. 3419-3426 ◽  
Author(s):  
Eve Maubec ◽  
Peter Petrow ◽  
Isabelle Scheer-Senyarich ◽  
Pierre Duvillard ◽  
Ludovic Lacroix ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Therapeutic Option ◽  
Progression Free Survival ◽  
Phase Iii ◽  
First Line ◽  
Serious Adverse Events ◽  
Ras Mutations ◽  
Egfr Inhibition

PurposeTo evaluate the efficacy and safety of cetuximab, a monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), as a first-line monotherapy in patients with unresectable squamous cell carcinoma of the skin (SCCS).Patients and MethodsThirty-six patients received cetuximab (initial dose of 400 mg/m2followed by subsequent weekly doses of 250 mg/m2) for at least 6 weeks with a 48-week follow-up. The primary end point was the disease control rate (DCR) at 6 weeks (according to Response Evaluation Criteria in Solid Tumors [RECIST] criteria). Secondary end points included best response rate, overall survival, progression-free survival (PFS), and toxicity assessment. Association of treatment efficacy with RAS mutations or FcγR genotypes was investigated.ResultsMedian age of the study population was 79 years. DCR at 6 weeks was obtained in 25 of 36 patients (69%; 95% CI, 52% to 84%) of the intention-to-treat population. The best responses were eight partial responses and two complete responses. There were no cetuximab-related deaths. There were three related serious adverse events: two grade 4 infusion reactions and one grade 3 interstitial pneumopathy. Grade 1 to 2 acne-like rash occurred in 78% of patients and was associated with prolonged PFS. One HRAS mutation was identified. Combined FcγRIIa-131H/H and/or FcγRIIIa-158V/V polymorphisms were not associated with the clinical outcomes.ConclusionAs a first-line treatment in patients with unresectable SCCS, cetuximab achieved 69% DCR. A randomized phase III trial is warranted to confirm that cetuximab may be considered as a therapeutic option especially in elderly patients. The low frequency of RAS mutations in SCCS makes SCCS tumors attractive for EGFR inhibition.

scholarly journals Pharmacologically Induced Cutaneous Squamous Cell Carcinoma

2020 ◽  
Author(s):  
Natalia García
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Signaling Pathways ◽  
Squamous Cell ◽  
Molecular Mechanisms ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Clinical Behavior ◽  
Mutational Burden ◽  
Therapeutic Landscape ◽  
Increased Risk

Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. Several drugs have been developed for CSCC treatment, but the disease may actually be induced by drugs as well. Molecular mechanisms underlie pharmacologically-induced CSCC, and a sound knowledge of them could help physicians better tackle this tumor. 

PD-1 Blockade With Concurrent Radiotherapy for Locally Advanced Inoperable Cutaneous Squamous Cell Carcinoma

2021 ◽  
pp. 120347542110642
Author(s):  
Kurian Joseph ◽  
John Walker ◽  
Hamid Raziee ◽  
Salman Faruqi ◽  
Michael Smylie
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Tumor Response ◽  
Therapeutic Option ◽  
Locally Advanced ◽  
Safety Data ◽  
Best Supportive Care ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Grade 3

Introduction For patients with locally advanced cutaneous squamous cell carcinoma (LA-cSCC), radiotherapy alone (RT) is often the only treatment option with modest tumor response. We report the outcomes of using combination of programmed cell death protein-1 (PD-1) inhibitor and RT in the treatment of inoperable LA-cSCC. The study presents the efficacy and safety data for the patients with LA-cSCC treated with this combination. Methods During the period 2018-2020, a total of 7 patients with biopsy proven inoperable LA-cSCC were treated with combination of PD-1 inhibitor cemiplimab and concurrent RT (Cem-RT). The patients were followed up for safety and efficacy of the Cem-RT regimen and the primary endpoints were objective tumor response and toxicity. Results The median age of patients was 68 years (range, 64-94). All patients had ECOG performance score 0-1. Six patients initially received cemiplimab and concurrent RT was added to PD-1 inhibitor when there was an inadequate therapeutic response. One patient received concurrent Cem-RT. RT with PD-1 antibody was well tolerated. Six patients developed grade ≤2 dermatitis and 1 patient (patient no. 3) developed acute grade 3 skin reaction. During the post-RT follow up, 3 patients discontinued cemiplimab due to significant toxicities. At the time of reporting , 5 patients remain in complete remission. One patient developed lung metastasis and is currently receiving best supportive care. Conclusions The Cem-RT combination was safe and well tolerated with significant tumor response suggesting Cem-RT may be a viable therapeutic option for LA-cSCC. Our hypothesis generating data support the rationale for future prospective studies.

scholarly journals Quality of life and clinical and demographic characteristics of patients with cutaneous squamous cell carcinoma submitted to tumor resection by double-bladed scalpel

2019 ◽  
Vol 94 (3) ◽  
pp. 304-312
Author(s):  
Daniel Ongaratto Barazzetti ◽  
Pedro Henrique Ongaratto Barazzetti ◽  
Bárbara Thomé Cavalheiro ◽  
Jorge Bins Ely ◽  
Daniel Holthausen Nunes ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Tumor Resection ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Demographic Characteristics

scholarly journals Therapeutic Perspectives for the Perioperative Period in Oral Squamous Cell Carcinoma (OSCC)

2022 ◽  
Vol 2 ◽  
Author(s):  
Antoine Galmiche ◽  
Zuzana Saidak ◽  
Jérémie Bettoni ◽  
Martial Ouendo ◽  
Sylvie Testelin
Keyword(s):  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Tumor Resection ◽  
Surgical Care ◽  
Oncological Outcome ◽  
Perioperative Period ◽  
Complex Nature ◽  
Neoadjuvant Immunotherapy

The perioperative period is the relatively short window of time, usually measured in days or weeks, around the surgical procedure. Despite its short duration, this time period is of great importance for cancer patients. From a biological point of view, the perioperative period is complex. Synchronous with primary tumor removal, surgery has local and distant consequences, including systemic and local inflammation, coagulation and sympathetic activation. Furthermore, the patients often present comorbidities and receive several medical prescriptions (hypnotics, pain killers, anti-emetics, hemostatics, inotropes, antibiotics). Because of the complex nature of the perioperative period, it is often difficult to predict the oncological outcome of tumor resection. Here, we review the biological consequences of surgery of Oral Squamous Cell Carcinoma (OSCC), the most frequent form of primary head and neck tumors. We briefly address the specificities and the challenges of the surgical care of these tumors and highlight the biological and clinical studies that offer insight into the perioperative period. The recent trials examining neoadjuvant immunotherapy for OSCC illustrate the therapeutic opportunities offered by the perioperative period.

Sign in / Sign up

Export Citation Format

Share Document